Table 4. Summary of the concentrations measured in GD patients and controls as well as in our experience of adding exogenous lipids.

|                          | Sphingolipid quantification in plasma (nM) | Sphingolipid quantification in RBCs (nM) |
|--------------------------|---------------------------------------------|------------------------------------------|
|                          | GL1 | Lyso-GL1 | S1P | Sph | GL1 | Lyso-GL1 | S1P | Sph |
| **Summary of the results:** |     |          |     |     |     |          |     |     |
| Median in controls (obtained from Chipeaux et al., 2017) | 3844 | 1.6 | 1609 | 6.9 | 82 | 5.2 | 1274 | 4.0 |
| Maximum values measured in GD UT patient | 18021 | 217 | 7127 | 23 | 204 | 184 | 4071 | 21 |
| **Exogenous lipids added on control blood:** |     |          |     |     |     |          |     |     |
| Concentration to add to control samples | 14000 | 220 | 5500 | 16 |     |     |     |     |
| Concentration in RBCs at T0 |     |     |     |     | 74 | 5.4 | 960 | 3.9 |
| Concentration in RBCs (2 hours of incubation) |     |     |     |     | 78 | 107 | 4168 | 12 |